Affiliation:
1. Endocrine Department, Second Affiliated Hospital of Soochow University,
Suzhou, China
Abstract
AbstractThe aim of the study was to explore the clinical features related to early
hypothyroidism and the relationship between the changes of thyrotropin receptor
antibodies (TRAb) and early hypothyroidism in the course of 131I
treatment for Graves’ disease. This study was a retrospective observation,
including 226 patients who received the first 131I treatment. The
general information and laboratory tests were collected before and after
131I treatment, and the laboratory data affecting the difference
in disease outcome were analyzed. According to the changes of antibodies in the
third month, whether the changes of antibodies were involved in the occurrence
of early-onset hypothyroidism was analyzed. Early onset hypothyroidism occurred
in 165 of 226 patients, and the results showed that the incidence of early
hypothyroidism was higher in patients with low baseline TRAb level (p=0.03) and
increased TRAb after treatment (p=0.007). Both baseline TRAb levels (p<0.001)
and the 24-hour iodine uptake rate (p=0.004) are significant factors influencing
the changes in TRAb. The likelihood of a rise in TRAb was higher when the
baseline TRAb was less than 18.55 U/l and the 24-hour iodine uptake level
exceeded 63.61%. Low baseline and elevated post-treatment levels of TRAb were
significantly associated with early-onset hypothyroidism after 131I
treatment. Monitoring this index during RAI treatment is helpful in identifying
early-onset hypothyroidism and mastering the clinical outcome and prognosis of
Graves’ disease.
Reference21 articles.
1. Increased TRAb and/or low anti-TPO titers at diagnosis of Graves' disease
are associated with an increased risk of developing ophthalmopathy after
onset;M Lantz;Exp Clin Endocrinol Diabetes,2014
2. Yersinia enterocolitica provides the link between thyroid-stimulating antibodies
and their germline counterparts in Graves' disease;C E Hargreaves;J Immunol,2013
3. Shifting trends and informed decision-making in the management of Graves’
disease;C D Seib;Thyroid,2020
4. Predictors of treatment failure, incipient hypothyroidism, and weight gain
following radioiodine therapy for Graves' thyrotoxicosis;F W Gibb;J Endocrinol Invest,2013
5. Age and gender predict the outcome of treatment for Graves'
hyperthyroidism;A Allahabadia;J Clin Endocrinol Metab,2000